Nucleus Biologics has launched the Krakatoa K500, a pod-based system designed to manufacture sterile cell culture media and buffers at point of use. The Krakatoa K500 on-demand media system is intended for bioreactor-scale workflows in biologics and advanced therapy manufacturing.
Krakatoa K500 on-demand media system targets 35–500 litre production
According to the company, the system can produce 35–500 litres of sterile media or buffers in a single automated run. Nucleus Biologics said the platform is designed to reduce reliance on centralised liquid preparation and associated cold-chain transport and storage.
The company states that the process requires less than 15 minutes of hands-on time and can produce up to 500 litres in under three hours, depending on pod size.
Pod-based design supports closed, single-use workflows
The Krakatoa K500 uses pre-formulated, powder-filled pods and a closed, single-use workflow. In addition, the system includes continuous inline monitoring of pH, conductivity and turbidity during each run.
Nucleus Biologics said the platform generates automated digital batch records and supports traceability to help enable GMP-aligned operation and audit readiness.
Nucleus Biologics has launched the Krakatoa K500 pod-based system for on-demand sterile media and buffer manufacturing.
QR-code execution and analytics support batch documentation
Each run is initiated using a QR-code-driven workflow intended to standardise formulation execution. As a result, the company positions the system for use cases where repeatability, documentation and process control are required across multiple manufacturing sites.
Nucleus Biologics also indicated that the system is designed to support co-location of media and buffer preparation with bioproduction, particularly in settings where liquid supply chains create time or capacity constraints.
Related coverage is available in the Life Sciences Global News Laboratory Science & Tools section.
